# Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/quality-of-life-in-patients-with-advanced-renal-cell-carcinoma-given-nivolumab/

## Facts

| Field | Value |
| --- | --- |
| Author Names | David Cella,Viktor Grünwald,Paul Nathan,Justin Doan,Homa Dastani,Fiona Taylor,Bryan Bennett,Michael DeRosa,Scott Berry,Kristine Broglio,Elmer Berghorn,Robert J. Motzer |
| Citations | 220 |
| DOI | 10.1016/s1470-2045(16)30125-5 |
| Fields | Economics, Econometrics and Finance,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2415125269 |
| PMID | 27283863 |
| Type | article |
| Year | 2016 |

## Paper authors

- [David Cella](https://scholariq.org/researchers/david-cella/)
- [Bryan Bennett](https://scholariq.org/researchers/bryan-bennett/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Paper topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.